Please login to the form below

Not currently logged in
Email:
Password:

Beleodaq

This page shows the latest Beleodaq news and features for those working in and with pharma, biotech and healthcare.

AZ signs two more deals in cancer immunotherapy

AZ signs two more deals in cancer immunotherapy

The latter is in the same class as Merck &Co's Zolinza (vorinostat), Novartis' Farydak (panobinostat) and Spectrum Pharmaceuticals' Beleodaq (belinostat), which are approved for various haematological cancers.

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics